A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
暂无分享,去创建一个
Ming‐Lung Yu | M. Yeh | Chung‐Feng Huang | C. Dai | Po-Cheng Liang | M. Hsieh | W. Chuang | M. Hsieh | Jeng‐Fu Yang | Pei-Chien Tsai | Chih-Wen Wang | Ta-Wei Liu | Tyng-Yuan Jang | Po-Yao Hsu | Yu-Ju Wei | Yi‐Hung Lin | Ching-I Huang | Jee‐Fu Huang
[1] Ming‐Lung Yu,et al. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan , 2022, The Kaohsiung journal of medical sciences.
[2] Ming‐Lung Yu,et al. Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021 , 2022, Journal of the Formosan Medical Association.
[3] Ming‐Lung Yu,et al. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan , 2021, BMJ Open.
[4] Mark R. Marten,et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.
[5] Shang-Jyh Hwang,et al. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C) , 2020, Gut.
[6] Ming‐Lung Yu,et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan , 2020, Clinical and molecular hepatology.
[7] H. Nomura,et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort , 2020, Hepatology International.
[8] G. Dore,et al. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. , 2020, The Journal of infectious diseases.
[9] J. Pawlotsky,et al. Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.
[10] C. James,et al. The impact of COVID-19 on hepatitis elimination , 2020, The Lancet Gastroenterology & Hepatology.
[11] R. Koretz. USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty) , 2020, Annals of Internal Medicine.
[12] Ming‐Lung Yu,et al. Importation of SARS-CoV-2 infection leads to major COVID-19 epidemic in Taiwan , 2020, International Journal of Infectious Diseases.
[13] Sheng-Nan Lu,et al. Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017 , 2020, Hepatology communications.
[14] A. Tamori,et al. Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West , 2020 .
[15] J. Kao,et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[16] J. Kao,et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[17] Stephen R. Spriggs,et al. CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[18] Ming‐Lung Yu,et al. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy , 2020, Clinical and molecular hepatology.
[19] M. Ghany,et al. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection , 2020 .
[20] Ding‐Shinn Chen. Taiwan commits to eliminating hepatitis C in 2025. , 2019, The Lancet. Infectious diseases.
[21] T. Hallett,et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model , 2019, The Lancet.
[22] J. Lazarus,et al. Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.
[23] Ming‐Lung Yu,et al. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.
[24] T. Tseng,et al. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.
[25] Ming‐Lung Yu,et al. Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C , 2015, Medicine.
[26] A. Moorman,et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[28] Ming‐Lung Yu,et al. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.
[29] P. Marcellin,et al. Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity , 2006, Alimentary pharmacology & therapeutics.
[30] Y. Liaw,et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. , 2006, Hepatology.
[31] V. de Lédinghen,et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.
[32] Ming‐Lung Yu,et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. , 2002, Epidemiology and infection.
[33] Ming‐Lung Yu,et al. Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan , 2001, Journal of medical virology.
[34] G. Ioannou,et al. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.
[35] Chien-Hung Chen,et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.